Medical therapy for rheumatoid arthritis - Value for money?

Rheumatology

Volumn 40, Issue 9, 2001, Pages 961-964

  Lambert, C M ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; AZATHIOPRINE; CARDIAC AGENT; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; METHOTREXATE; PENICILLAMINE; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG THERAPY; EDITORIAL; FEMALE; HEALTH CARE; HEALTH ECONOMICS; HUMAN; MALE; MEDICAL DECISION MAKING; MODEL; MONEY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SIDE EFFECT;

EID: 0034789587     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/40.9.961     Document Type: Editorial

References (32)

1. The burden of rheumatoid arthritis: Facts and figures
2. The economic cost and psychological impact of musculo-skeletal conditions
3. The costs of rheumatoid arthritis: A patient-orientated study of chronic disease costs
4. A multi-center study of annual health service utilization and costs in rheumatoid arthritis
5. Direct medical costs unique to people with arthritis
6. The cost of rheumatoid arthritis
7. Economic burden of rheumatoid arthritis: A systematic review
8. Indirect and non-medical costs among people with rheumatoid arthritis and osteoarthritis compared with non-arthritis controls
9. The lifetime costs of rheumatoid arthritis
10. The impact of rheumatoid arthritis on employment status in the early years of disease: A UK community-based study
11. Current therapeutic options: Non-biologic agents
12. Termination of slow acting anti-rheumatic therapy in rheumatoid arthritis: A 14 year prospective evaluation of 1017 consecutive starts
13. Long term drug therapy for rheumatoid arthritis in seven rheumatology private practices. 2. Second line drugs and prednisolone
14. The epidemiology of drug treatment failure in rheumatoid arthritis
15. Treatment strategy, disease activity, and outcome in four cohorts of patients with early rheumatoid arthritis
16. The total cost of drug therapy for rheumatoid arthritis: A model based on costs of drug, monitoring and toxicity
17. Modeling the lifetime costs of rheumatoid arthritis
18. Health economics as an aspect of health outcome: Basic principles and application in rheumatoid arthritis
19. Health economic models: A question of balance-Summary of an open discussion on the pharmaco-economic evaluation of non-steroidal anti-inflammatory drugs
20. Markov models in medical decision making
21. Economic consequences of the progression of rheumatoid arthritis in Sweden
22. Statistical analysis of cost effectiveness data
23. Guidelines for authors and peer reviewers of economic submissions to the BMJ
24. Randomised comparison of combined step down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis
25. Cost effectiveness and cost utility of combination therapy in early rheumatoid arthritis: Randomised comparison of combined step down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone
26. A cost-effectiveness analysis of cyclosporine in rheumatoid arthritis
27. A cost effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis
28. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
29. Infliximab and methotrexate in the treatment of rheumatoid arthritis
30. New treatments in arthritis: The use of TNF alpha blockers in adults with rheumatoid arthritis. Report of a working party of the British Society for Rheumatology
31. Cost evaluation of novel therapeutics in rheumatoid arthritis (CENTRA): A decision analysis model
32. Direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: A 12 year study